Business

At Illumina, the faster we can innovate, the more lives we can help save.  As a genomics pioneer, we have proven through focused and continued innovation how unlocking the power of the genome can exponentially improve the human condition. Our ability to drive patient outcomes has made us a trusted partner in healthcare. Today, we’re providing tools that enable the next generation of researchers and clinicians to usher in the future of personalized medicine. Innovating at the intersection of technology, biology, and health, we are re-imagining what’s possible for clinicians, transforming how they detect, diagnose, and treat cancer, and rare, infectious, and genetic diseases.

Videos from this campaign

Illumina at Dream Big
Illumina and Minderoo Foundation.

Content from this campaign

Innovation & Technology

Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions
Illumina, a global leader in DNA sequencing and array-based technologies, today shared key customer-focused announcements and presentations it will make at the Advances in Genome Biology and Technology (AGBT) General Meeting, taking place June 6–9 in Orlando, Fla.

Innovation & Technology

Can Wastewater Surveillance Protect Public Health?
Whether we realize it or not, we leave clues to our health every time we use the bathroom.

Health & Healthcare

Illumina CEO Reflects on the State of Genomics in 2021
COVID-19 inflicted tremendous suffering in 2021, taking almost 3.5 million lives this year, more than died from HIV/AIDS, tuberculosis and malaria combined last year.

Events, Media & Communications

Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021
Illumina, Inc. (NASDAQ:ILMN) today announced that it will host its first Environment, Social and Corporate Governance (ESG) focused investor event at 11:00 am Pacific Time (2:00 pm Eastern Time), Tuesday, November 16, 2021.

Awards, Ratings & Rankings

Illumina Wins Reddot 2021 Award: Genomic Sequencing System NextSeq 1000/2000
Illumina's NextSeq 1000/2000 sequencing systems are based on a technology that leverages light to decipher the genome. The instruments are used, among other things, to determine the genetic profile of the SARS-CoV-2 virus and its variants.

Responsible Business & Employee Engagement

CSR Q&A With Illumina's Chief Financial Officer

Events, Media & Communications

Bringing Bright Minds Together at SPARK
When will precision medicine truly take off? How can healthcare be more inclusive? What are the next steps in the fight against COVID and future pandemics? What does a global Bio Force look like?
Illumina logo

More from Illumina

  1. Community
    By sharing our time, talent, and technology, we aim to inspire, support, and empower our communities, our employees, and the next generation.

  2. Access
    Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in...

  3. Business
    At Illumina, the faster we can innovate, the more lives we can help save. As a genomics pioneer, we have proven through focused and continued...

  4. Environment
    We are committed to integrating environmental stewardship into the way we operate. We recognize the importance of the environment in creating a...

  5. Operating Responsibly
    Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring that the technology we create and the data we...

  6. People
    Harnessing the world’s best talent and giving them the opportunity to thrive allows us to make world-changing leaps in human health and beyond. Our...